The global drug markets shocked by the coronavirus are giving generic drugmaker Phlow a chance to return more manufacturing to the U.S. But millions of dollars in government support won’t be enough unless the company learns from other drugmakers’ past mistakes.
The reliance on foreign drugmakers has long been deemed a national security risk, but the U.S. has been scattered in its efforts to lure more domestic manufacturing. Past efforts failed when an immediate threat passed and funding dried up or when companies propped up with federal dollars couldn’t secure other buyers.
“The chance of success on their own without ...